Offers actionable preclinical mechanistic evidence that modulating gut microbiota or supplementing SCFAs (butyrate) — and targeting the TLR4/MyD88/NF-κB inflammatory axis — may be a viable therapeutic strategy for PD, though the herbal formula's active constituents remain undefined for direct drug…

Relevance to Parkinson's lies in highlighted, potentially actionable pathways (oral-to-gut microbial translocation, inflammation, BBB and metabolite-mediated neural effects) that could yield novel intervention or biomarker avenues, though the paper is a broad review with limited mechanistic…

Pins HDAC3 as an actionable anti‑inflammatory/anti‑pyroptotic target with in vivo neuroprotection, supporting further preclinical development or repurposing of selective HDAC3 inhibitors for PD therapeutics.

By linking validated mitophagy-related genes to both CNS cell-specific and peripheral immune alterations in PD, the study provides actionable candidate targets and biomarkers for mitochondrial-focused therapeutic development and immune-modulating strategies.

Neuroinflammation and oxidative stress are key drivers of Parkinson's pathology, so TRF's modulation of NF-κB and Nrf2 pathways suggests translational repurposing potential, but lack of PD-specific models and dopaminergic/alpha-synuclein data means focused follow-up is needed.

Targeting microglial inflammation and oxidative stress is relevant to Parkinson's disease neuroprotection, but this study is limited to in vitro BV2 assays without mechanism, active compound identification, or PD-relevant models, so the findings are promising but preliminary for therapeutic…

While not addressing disease modification, the study provides actionable clinical evidence that apomorphine confers broad symptomatic benefits—including non-motor domains—supporting its use, informing endpoint selection for trials, and guiding symptomatic therapeutic strategies despite limited…

For Parkinson's research, the paper highlights actionable pathways linking the microbiome to neuroinflammation and potentially alpha-synuclein pathology and points to readily testable therapeutic and biomarker strategies (dietary modulation, probiotics/FMT, metabolite-targeting drugs) that can be…

Distinguishing disease-driven daytime sleepiness from medication-associated fatigue highlights modifiable targets for symptomatic management and informs therapeutic development and trial stratification for PD non-motor symptoms.

The paper has moderate translational value: it supports routine HUTT screening to prevent falls and to stratify or monitor patients for symptomatic autonomic therapies and clinical trials, but offers limited mechanistic or novel therapeutic-target insights for disease-modifying drug discovery.

Identifies a druggable, inflammation-driven axis (NLRP3) closely tied to core PD pathologies and compiles plant-derived modulators with translational promise, making it a useful roadmap for prioritizing leads and designing preclinical studies.

Synthesizes actionable mechanistic insights and translational therapeutic avenues (immunotherapy, cell replacement, gene therapy), helping researchers prioritize targets, repurposing opportunities, and design of multi-modal, clinically relevant Parkinson’s interventions.

Valuable for therapeutic discovery because it links biologically plausible, inflammation- and proteostasis-targeting mechanisms to early clinical data and clearly identifies manufacturability, potency, and biomarker gaps that must be resolved to enable rigorous disease-modifying MSC trials.

By clarifying how cell type and delivery route map onto distinct mechanisms and clinical goals, the framework aids prioritization of translational strategies, trial design, and selection of biomarkers for PD disease-modifying therapy development.

Highlights TAAR1 as a translationally actionable target to rebalance monoaminergic systems and potentially slow Parkinson's pathology, offering a clear therapeutic focus despite limited direct coverage of PD-specific mechanisms like alpha‑synuclein or mitochondrial dysfunction.

Relevant to Parkinson’s therapeutic discovery because it consolidates actionable targets and translational approaches (autophagy pathways, inflammasome/CMA modulation, biomarkers, gene/RNA therapies, and screening technologies) that can guide target selection and repurposing, although its value is…

It identifies PD‑relevant mechanisms (Nrf2 activation, NF‑κB inhibition, BDNF modulation, enhanced autophagic clearance, mitochondrial protection, and reduced protein aggregation) that support further lead optimization and translational work, but its utility is limited by being a narrative review…

This paper signals that systemic inflammation and vascular comorbidity are important stratifiers and potential modifiable risk axes for PD research—supporting vascular surveillance, cohort stratification, and targeted mechanistic work on inflammation–vascular interactions rather than immediate…

Although centered on MSA, the study defines an actionable astrocyte-mediated pathway (FABP5 → TNFα → ferroptosis/GPX3 loss) linking α-synuclein pathology to glial-driven degeneration, highlighting targets and modalities (FABP5 inhibition, TNF modulation, ferroptosis/GPX3-directed therapies) with…

The PD-specific enrichment for mitochondrial, vesicle-trafficking, and stress-response pathways yields actionable mechanistic priorities for Parkinson’s therapeutic discovery and argues for genetically informed, metabolism-targeted strategies distinct from those for AD.